Endothelial progenitor cells (EPCs) are known to play a significant role in reendothelialization and vascular repair. Recently, a mineralocorticoid receptor was demonstrated to be expressed by EPCs. The study aimed to evaluate a potential influence of eplerenone treatment on the total number of EPCs in patients with chronic heart failure.
Methods:
Eighty-seven male patients with chronic heart failure were included (age: 23–83 years; body mass index 29.1 ± 5.1 kg/m2; New York Heart failure classification (NYHA) I: 29 patients, NYHA II: 32 patients, NYHA III: 26 patients). Numbers of circulating EPCs were quantified immediately using flow cytometry. Twenty-eight patients received therapy with eplerenone. Patients were further characterized by echocardiography, spirometry and laboratory markers.
Results:
Patients with ongoing eplerenone administration showed higher levels of circulating cells expressing CD34+ (p<0.05) and CD34+KDR+ (p<0.05) and CD34+CD133+KDR+ cells (p<0.05). The effects of eplerenone treatment could be shown to be independent of NYHA status, genesis of the underlying cardiovascular morbidity, left ventricular function and co-medication.
Conclusion:
Patients with chronic heart failure treated with eplerenone show higher numbers of EPCs. The clinical benefit for treatment with eplerenone has been demonstrated even for patients with mild heart failure and might be partially mediated by EPCs.
UrbichCDimmelerS. Endothelial progenitor cells: Characterization and role in vascular biology. Circ Res2004; 95: 343–353.
2.
JujoKIiMLosordoDW. Endothelial progenitor cells in neovascularization of infarcted myocardium. J Mol Cell Cardiol2008; 45: 530–544.
3.
HillJMZalosGHalcoxJPJ. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med2003; 348: 593–600.
4.
Schmidt-LuckeCRossigLFichtlschererS. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: Proof of concept for the clinical importance of endogenous vascular repair. Circulation2005; 111: 2981–2987.
5.
HumpertPMEichlerHLammertA. Adult vascular progenitor cells and tissue regeneration in metabolic syndrome. Vasa2005; 34: 73–78.
6.
ImanishiTMoriwakiCHanoT. Endothelial progenitor cell senescence is accelerated in both experimental hypertensive rats and patients with essential hypertension. J Hypertens2005; 23: 1831–1837.
7.
GeorgeJHerzIGoldsteinE. Number and adhesive properties of circulating endothelial progenitor cells in patients with in-stent restenosis. Arterioscler Thromb Vasc Biol2003; 23: e57–e60.
8.
JungCRafnssonAShemyakinA. Different subpopulations of endothelial progenitor cells and circulating apoptotic progenitor cells in patients with vascular disease and diabetes. Int J Cardiol2010; 3: 368–372.
9.
ChenJZZhangFRTaoQM. Number and activity of endothelial progenitor cells from peripheral blood in patients with hypercholesterolaemia. Clin Sci (Lond)2004; 107: 273–280.
10.
KisselCKLehmannRAssmusB. Selective functional exhaustion of hematopoietic progenitor cells in the bone marrow of patients with postinfarction heart failure. J Am Coll Cardiol2007; 49: 2341–2349.
11.
Nonaka-SarukawaMYamamotoKAokiH. Circulating endothelial progenitor cells in congestive heart failure. Int J Cardiol2007; 119: 344–348.
12.
ValgimigliMRigolinGMFuciliA. CD34+ and endothelial progenitor cells in patients with various degrees of congestive heart failure. Circulation2004; 110: 1209–1212.
13.
FritzenwangerMLorenzFJungC. Differential number of CD34+, CD133+ and CD34+/CD133+ cells in peripheral blood of patients with congestive heart failure. European Journal of Medical Research2009; 14: 113–117.
14.
PellicciaFPasceriVCianfroccaC. Endothelial progenitor cells in patients with coronary artery disease and left ventricular dysfunction. Coron Artery Dis2009; 20: 303–308.
15.
SchachingerVAssmusBBrittenMB. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: Final one-year results of the TOPCARE-AMI Trial. J Am Coll Cardiol2004; 44: 1690–1699.
16.
Van CraenenbroeckEMConraadsVM. Endothelial progenitor cells in vascular health: Focus on lifestyle. Microvasc Res2010; 79: 184–192.
17.
PellicciaFPasceriVCianfroccaC. Angiotensin II receptor antagonism with telmisartan increases number of endothelial progenitor cells in normotensive patients with coronary artery disease: a randomized, double-blind, placebo-controlled study. Atherosclerosis2010; 210: 510–515.
18.
ErbsSBeckEBLinkeA. High-dose rosuvastatin in chronic heart failure promotes vasculogenesis, corrects endothelial function, and improves cardiac remodeling – results from a randomized, double-blind, and placebo-controlled study. Int J Cardiol2011; 146: 56–63.
19.
ThumTSchmitterKFleissnerF. Impairment of endothelial progenitor cell function and vascularization capacity by aldosterone in mice and humans. Eur Heart J2010; 32: 1275–1286.
20.
ZannadFMcMurrayJJKrumH. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med2010; 364: 11–21.
21.
LadageDSchutzebergNDartschT. Hyperaldosteronism is associated with a decrease in number and altered growth factor expression of endothelial progenitor cells in rats. Int J Cardiol2011; 149: 152–156.
22.
FadiniGPMiorinMFaccoM. Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J Am Coll Cardiol2005; 45: 1449–1457.
23.
JungCFischerNFritzenwangerM. Endothelial progenitor cells in adolescents: Impact of overweight, age, smoking, sport and cytokines in younger age. Clin Res Cardiol2009; 98: 179–188.
24.
FunderJW. Reconsidering the roles of the mineralocorticoid receptor. Hypertension2009; 53: 286–290.
25.
IraqiWRossignolPAngioiM. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: Insights from the Eplerenone Post-acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. Circulation2009; 119: 2471–2479.
26.
KobayashiNFukushimaHTakeshimaH. Effect of eplerenone on endothelial progenitor cells and oxidative stress in ischemic hindlimb. Am J Hypertens2010; 23: 1007–1013.
27.
MichowitzYGoldsteinEWexlerD. Circulating endothelial progenitor cells and clinical outcome in patients with congestive heart failure. Heart2007; 93: 1046–1050.
28.
LeoneAMValgimigliMGiannicoMB. From bone marrow to the arterial wall: The ongoing tale of endothelial progenitor cells. Eur Heart J2009; 30: 890–899.
29.
TousoulisDAndreouITsiatasM. Effects of rosuvastatin and allopurinol on circulating endothelial progenitor cells in patients with congestive heart failure: The impact of inflammatory process and oxidative stress. Atherosclerosis2011; 214: 151–157.
30.
MaceneaneyOJKushnerEJVan GuilderGP. Endothelial progenitor cell number and colony-forming capacity in overweight and obese adults. Int J Obes (Lond)2009; 33: 219–225.
